Načítá se...
Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics
Recently, there has been a shift in the schizophrenia field focusing on restoring glutamate signaling. Extensive preclinical data suggests that mGlu(5) PAMs could have efficacy in all three symptom domains but there is concern of potential adverse effects. New insights into mechanisms underlying thi...
Uloženo v:
| Vydáno v: | Curr Opin Pharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4318747/ https://ncbi.nlm.nih.gov/pubmed/25462291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2014.11.003 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|